From Fragile to Formidable: Solving Resveratrol's Instability with Liposomal Delivery
Resveratrol is a potent antioxidant, but its extreme sensitivity to light, oxygen, and heat leads to rapid degradation—efficacy can drop 50–70% within weeks. This instability poses a significant challenge for skin and cardiovascular applications. Through liposomal encapsulation, we've transformed this fragile molecule into a stable, high-performance ingredient.
Read more →
Fisetin: How Does It Become a Powerful Ally as a "Cellular Cleaner"?
Found abundantly in strawberries, apples, onions, and other foods, Fisetin is a polyphenol with multi-target bioactivity. It shows unique anti-aging potential by combating age-related damage through senolytic activity, autophagy activation, and upregulation of the SIRT1 pathway.
Read more →
Why a "Systems" View Matters in Anti-Aging
At Humanpro, we believe discussions on slowing aging often highlight single molecules. Biology, however, reveals a more complex picture: aging is a systemic, multidimensional process. It's not a single failure but a loss of coordination across interconnected cellular networks.
Read more →
Why Peptides Often“Fail”? Delivery Formulation is Key
Even the most potent signaling molecule fails if it cannot reach its target. As the industry's leading expert in precise peptide delivery, Humanpro systematically breaks down how to build a direct “formulation bridge” to the hair follicle for star ingredients like Blue Copper Peptides (e.g., AHK-Cu / GHK-Cu).
Read more →
Beyond the "Miracle Ingredient": A Modular Formulation Strategy for Hair Loss
When tackling hair loss formulation, a systematic approach consistently outperforms the search for a single “miracle ingredient.” As a formulator focused on synergy, working on active ingredient and delivery system development at Humanpro, I believe effective products are built on functional modules, not isolated actives. Here’s a practical two-module framework: “Nutrient Supply + Antioxidant Defense” and “Anti-DHT + Anti-Fibrosis.”
Read more →
What is the foundation of a successful Phase II clinical trial?
In drug development, Phase II is the critical bridge that validates concepts and assesses efficacy. Its success is never accidental; it is deeply rooted in a rigorous data chain from preclinical stages through Phase I, and fundamentally dependent on high-purity, highly consistent research materials — an area where partners like Humanpro specialize in supporting translational and early clinical research.
Read more →
Featured SARMs Series: Molecular Optimization and Pharmacokinetic Enhancement
In the field of SARMs research, molecular structure optimization is a key pathway to enhancing compound performance and applicability. RAD150 (an esterified variant of RAD140) and ACP-105 represent two classes of structurally modified featured compounds. The former improves pharmacokinetic properties through an esterification strategy, while the latter stands out for its high selectivity in muscle and prostate safety studies. Humanpro is committed to providing these scientifically optimized research tools to help researchers conduct more precise mechanistic exploration and model development.
Read more →
Clinical Frontier SARMs Series: Innovative Research Tools Advancing Muscle Disease Treatments
In the pharmaceutical and biomedical research fields, clinical frontier SARMs (such as PF-06260414, GSK-2881078, and GLPG0492), as selective androgen receptor modulators that have entered clinical trials, represent potential breakthroughs in treating muscle wasting and metabolic diseases. Humanpro is committed to supplying the highest purity cutting-edge research materials, supporting your innovative R&D projects and facilitating the transition from lab to clinic.
Read more →
AC Series SARMs: New Advances in Non-Steroidal, Muscle-Selective Research Tools
In the field of anabolic research, non-steroidal Selective Androgen Receptor Modulators (SARMs) have attracted significant attention due to their potential tissue selectivity. The AC series SARMs, such as AC-262536 and AC-262,356, represent a new generation of research compounds designed to explore the mechanisms of muscle growth and strength enhancement while minimizing the side effects associated with traditional androgen therapies. Humanpro supplies high-purity AC series raw materials, providing reliable support for your preclinical research and drug development projects.
Read more →
MK Series SARMs: Advanced Tools for Exploring Muscle Protection and Tissue-Selective Research
In the field of selective androgen receptor modulator research, MK series compounds (such as MK-0773 and MK-4541) represent significant progress from muscle health studies to tissue-specific therapeutic exploration. MK-0773, a steroidal SARM that has entered Phase II clinical studies, provides a reference model for sarcopenia and osteoporosis research from preclinical to clinical stages. MK-4541 demonstrates potential in research for differentially modulating muscle anabolism and prostate tissue. Humanpro supports your complete research pipeline from basic science to translational medicine with high-purity, compliant research materials.
Read more →
LGD Series SARMs: Precision Research Tools for Exploring Muscle and Bone Metabolism
In the fields of sports nutrition and pharmaceutical research, LGD series SARMs (such as LGD-3303 and LGD-2226), as experimental selective androgen receptor modulators, offer a potential tissue-selective approach for research into muscle wasting and osteoporosis. PHMO is committed to supplying high-purity research materials to empower your R&D projects.
Read more →
SARMs: The Potential and Controversy of Selective Androgen Receptor Modulators
Selective androgen receptor modulators (SARMs) are emerging as one of the most promising drug candidates for the treatment of muscle atrophy, osteoporosis, and cancer cachexia. Compared to traditional synthetic androgens, SARMs aim to retain potent anabolic effects while significantly reducing androgen-related side effects. This article, drawing on cutting-edge research, provides an in-depth analysis of the scientific nature, research progress, and practical challenges of SARMs.
Read more →
FDA Faces Lawsuit Over NMN Legality — Industry Pushes Back
After months of inaction from the U.S. Food and Drug Administration (FDA), the Natural Products Association (NPA) has officially filed a lawsuit challenging the FDA’s position on β-Nicotinamide Mononucleotide (NMN) — a popular dietary supplement ingredient known as a direct precursor of NAD⁺.
Read more →